| Display title | Biology:Luspatercept |
| Default sort key | Luspatercept |
| Page length (in bytes) | 11,871 |
| Namespace ID | 3026 |
| Namespace | Biology |
| Page ID | 851476 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Len Stevenson |
| Date of page creation | 12:40, 12 February 2024 |
| Latest editor | imported>Len Stevenson |
| Date of latest edit | 12:40, 12 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. |
